Track topics on Twitter Track topics that are important to you
Alzheon Inc. (neurodegenerative disease drugs) filed for an initial public offering.
Alzheon is turning to the public markets to finance a new round of testing for its experimental Alzheimer’s disease drug. The Framingham, MA, company set a preliminary $80 million target for its ini...
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
Biopharmaceutical firm Alzheon has discovered an endogenous substance in the human brain that can block the formation of neurotoxic beta...Read More... The post Alzheon finds brain substance inhibits ...
In April, Alzheon attempted an initial public offering (IPO) to raise $80 million, but withdrew the offering. It has decided to try again, filing with the U.S. Securities and Exchange Commission (SEC)...
Alzheon, a tiny biotech based in the Boston area, had initially launched its roadshow for an IPO potentially worth up to $81 million at the beginning of April, only for it to announce that it would be...
Scientists with Framingham, Massachusetts-based Alzheon identified a substance in the human brain that inhibits the formation of beta-amyloid, the primary driver of Alzheimer’s disease. The substanc...
Alzheon tells prospective investors it believes beta-amyloid blocker ALZ-801 can succeed in pivotal trials by treating APOE4 subgroup.
Alzheon, Inc., is a clinical-stage biotechnology company focused on brain health, memory and aging, developing innovative treatments for Alzheimerâs disease and other neurode...
Alzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimerâs disease and other neurological and psychiatric disorders. Our lead clini...
We have published hundreds of Alzheon Inc. news stories on BioPortfolio along with dozens of Alzheon Inc. Clinical Trials and PubMed Articles about Alzheon Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alzheon Inc. Companies in our database. You can also find out about relevant Alzheon Inc. Drugs and Medications on this site too.
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...
Psychiatry is the study of mental disorders and their diagnosis, management and prevention. Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...